NO118491B - - Google Patents
Download PDFInfo
- Publication number
- NO118491B NO118491B NO159004A NO15900465A NO118491B NO 118491 B NO118491 B NO 118491B NO 159004 A NO159004 A NO 159004A NO 15900465 A NO15900465 A NO 15900465A NO 118491 B NO118491 B NO 118491B
- Authority
- NO
- Norway
- Prior art keywords
- nitrofurantoin
- vomiting
- crystal size
- nitromethane
- side effects
- Prior art date
Links
- 229960000564 nitrofurantoin Drugs 0.000 claims description 26
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 26
- 239000013078 crystal Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 9
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000012047 saturated solution Substances 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 description 9
- 230000008673 vomiting Effects 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US392023A US3401221A (en) | 1964-08-25 | 1964-08-25 | Treatment of urinary tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO118491B true NO118491B (fr) | 1970-01-05 |
Family
ID=23548942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO159004A NO118491B (fr) | 1964-08-25 | 1965-07-19 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US3401221A (fr) |
| JP (1) | JPS4924651B1 (fr) |
| AT (1) | AT261117B (fr) |
| BE (1) | BE668774A (fr) |
| DE (1) | DE1492055B1 (fr) |
| DK (1) | DK116132B (fr) |
| ES (1) | ES313664A1 (fr) |
| FI (1) | FI42961B (fr) |
| FR (1) | FR4844M (fr) |
| GB (1) | GB1040980A (fr) |
| IL (1) | IL23668A (fr) |
| NL (1) | NL6506369A (fr) |
| NO (1) | NO118491B (fr) |
| SE (1) | SE326186B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2348334C2 (de) * | 1973-09-26 | 1982-11-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs |
| DE3033919A1 (de) * | 1980-09-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung |
| US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
| US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
| US5178880A (en) * | 1989-07-25 | 1993-01-12 | Norwich Eaton Pharmaceuticals, Inc. | Liquid suspensions of nitrofurantoin |
| US5332832A (en) * | 1989-07-26 | 1994-07-26 | Procter & Gamble Pharmaceuticals, Inc. | Nitrofurantoin crystals |
| US20060002997A1 (en) * | 2002-08-23 | 2006-01-05 | Puneet Shamar | Nitrofurantoin controlled release dosage form |
-
1964
- 1964-08-25 US US392023A patent/US3401221A/en not_active Expired - Lifetime
-
1965
- 1965-05-19 NL NL6506369A patent/NL6506369A/xx unknown
- 1965-05-25 DE DE19651492055 patent/DE1492055B1/de active Pending
- 1965-06-01 ES ES0313664A patent/ES313664A1/es not_active Expired
- 1965-06-03 IL IL23668A patent/IL23668A/en unknown
- 1965-06-16 SE SE07949/65A patent/SE326186B/xx unknown
- 1965-06-22 DK DK316165AA patent/DK116132B/da unknown
- 1965-07-19 NO NO159004A patent/NO118491B/no unknown
- 1965-07-21 JP JP40043717A patent/JPS4924651B1/ja active Pending
- 1965-08-05 FR FR27293A patent/FR4844M/fr not_active Expired
- 1965-08-09 GB GB34070/65A patent/GB1040980A/en not_active Expired
- 1965-08-18 FI FI1983/65A patent/FI42961B/fi active
- 1965-08-24 AT AT774865A patent/AT261117B/de active
- 1965-08-25 BE BE668774D patent/BE668774A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE326186B (fr) | 1970-07-20 |
| IL23668A (en) | 1969-07-30 |
| GB1040980A (en) | 1966-09-01 |
| ES313664A1 (es) | 1965-09-01 |
| FR4844M (fr) | 1967-02-20 |
| DK116132B (da) | 1969-12-15 |
| JPS4924651B1 (fr) | 1974-06-25 |
| DE1492055B1 (de) | 1971-05-13 |
| US3401221A (en) | 1968-09-10 |
| AT261117B (de) | 1968-04-10 |
| NL6506369A (fr) | 1966-02-28 |
| BE668774A (fr) | 1965-12-16 |
| FI42961B (fr) | 1970-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3578174B2 (ja) | 神経−ａｉｄｓの治療におけるリルゾールの適応 | |
| DK167925B1 (da) | 9-substitueret guanin-monohydrat, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat, monohydrat til brug som terapeutisk aktivt middel, monohydrat til brug til behandling af virusinfektioner og anvendelse af et monohydrat til brug ved fremstilling af et medikament | |
| WO2011143872A9 (fr) | Forme cristalline de l'acétamide de (s)-4-hydroxy-2-oxo-1-pyrrolidine, son procédé de préparation et son utilisation | |
| JP2006501199A (ja) | ホモハリングトニンを含むセファロタキシンの製剤および投与方法 | |
| EP3023416B1 (fr) | Préparation de (-)-huperzine a | |
| ES2791295T3 (es) | Procedimiento para purificar ácido ferúlico y/o sales del mismo | |
| TWI747906B (zh) | 達格列淨新晶型及其製備方法和用途 | |
| JPH0515713B2 (fr) | ||
| CN107303390A (zh) | Dpp4抑制剂在制备治疗低氧性肺动脉高压药物中的用途 | |
| NO159004B (no) | Rapport- eller regnskapsmappe. | |
| CN110627792A (zh) | 一种己酮可可碱化合物 | |
| CN114533710A (zh) | 姜黄素在制备防治电离辐射致生殖系统损伤的药物中的应用 | |
| WO2015067130A1 (fr) | Forme cristalline iii du (s)-oxiracétam, son procédé de préparation, et application | |
| CN104083363B (zh) | 奥拉西坦或左旋奥拉西坦在制药领域中的新应用 | |
| CN106478570A (zh) | 二甲基胺4-o-乙酰基线叶旋覆花内酯a或其盐及其制备与应用 | |
| JPH06502190A (ja) | ジアセチルレインの製造方法 | |
| EP3068370A2 (fr) | Compositions pharmaceutiques stables | |
| RU2140277C1 (ru) | Противовоспалительное средство с иммуномодулирующими свойствами | |
| KR950702528A (ko) | 엔^지(n^g)-모노메틸-엘(l)-아르기닌 염화수소 유도체 및 패혈증성 쇼크의 치료에 있어서의 이들의 용도, (n^g-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock) | |
| CN114699422A (zh) | 脆弱拟杆菌的荚膜多糖提取物在制备防治阿尔茨海默病的药物中的应用 | |
| RU2095074C1 (ru) | Лекарственный препарат "фитопрополис-препарат" и способ его получения | |
| CN116120336B (zh) | 一种木瓜原花青素及其制备方法和应用 | |
| TWI622397B (zh) | 老鸛草鞣質之用途與老鸛草鞣質及阿黴素之用途 | |
| EP3130600B1 (fr) | Composé destiné à traiter les séquelles de l'ictus cérébral ischémique | |
| EP0449722B1 (fr) | Nouveaux complexes de l'acide tiaprofénique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs dérivés |